Novocure (NVCR) announces that it has advanced a new, flexible torso array into a clinical usability study.The updated array will be tested by patients and their caregivers at...
If you're a trend trader, consider that the strongest clear trend on the hourly chart exists on the 20 hour timeframe.The post NovoCure Ltd (NVCR): Price Down $-3.85 (-1.77)% Over...
The FDA has approved Novocure Ltd's (NASDAQ: NVCR) Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement for its LUNAR Phase 3 trial to 276...
A few of the country’s biggest retailers reported strong quarterly results on Tuesday… but, of course, the market didn’t care. In fact, a late plunge by all of...
SPECIAL ALERT: Remember, the May episode of the Zacks Ultimate Strategy Session is now available for viewing! Don’t miss your chance to hear: ▪ David Bartosiak and Dr....
Stocks took another small step backward from its record-setting pace on Tuesday as earnings season heats up. However, the losses over the past two days have been very orderly and...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Sell | Buy | Strong Buy |
| Technical Indicators | Sell | Strong Sell | Strong Sell | Strong Buy | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,402.22 | 2,432.06 | 2,400.30 | -32.65 | -1.34% | 2.31M | NASDAQ | |||
| 329.66 | 336.15 | 329.00 | -6.85 | -2.04% | 23.04M | NASDAQ | |||
| 186.34 | 187.49 | 182.60 | +0.78 | +0.42% | 8.32M | NASDAQ | |||
| 98.17 | 99.76 | 95.27 | +3.52 | +3.72% | 7.60M | NYSE | |||
| 2,511.35 | 2,527.78 | 2,492.06 | -16.07 | -0.64% | 2.67M | NASDAQ | |||
| 46.79 | 47.17 | 45.15 | +0.91 | +1.98% | 1.06M | NASDAQ | |||
| 40.29 | 41.19 | 39.51 | -0.51 | -1.25% | 1.18M | NASDAQ | |||
| 46.15 | 46.66 | 43.06 | +2.33 | +5.32% | 1.77M | NASDAQ | |||
| 31.93 | 33.25 | 31.52 | -1.13 | -3.42% | 3.97M | NASDAQ | |||
| 92.25 | 96.54 | 91.86 | -5.86 | -5.97% | 1.86M | NYSE | |||
| 59.26 | 64.96 | 56.85 | -1.47 | -2.42% | 243.65M | NYSE | |||
| 212.30 | 213.84 | 210.59 | +0.70 | +0.33% | 13.72M | NYSE | |||
| 231.97 | 234.39 | 231.15 | -4.72 | -1.99% | 4.24M | NYSE | |||
| 9.30 | 9.60 | 8.84 | +0.3000 | +3.33% | 32.73K | OTC Markets | |||
| 123.86 | 128.46 | 120.42 | -2.45 | -1.94% | 5.37M | NASDAQ |
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
